A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)

Trial Profile

A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs Enoblituzumab (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacodynamics
  • Sponsors MacroGenics
  • Most Recent Events

    • 21 Dec 2016 Status changed from recruiting to discontinued as Unable to accrue as planned for optional biopsies.
    • 05 Nov 2014 Planned End Date changed from 1 Mar 2014 to 1 Feb 2016 according to ClinicalTrials.gov record.
    • 05 Nov 2014 Planned primary completion date changed from 1 Mar 2014 to 1 Feb 2016 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top